Pathological Complete Response After Breast Cancer Therapy Linked to Better Survival

A large retrospective study from China has found that patients with breast cancer who achieve a pathological complete response after neoadjuvant therapy live longer without recurrence than those who do not, although the survival benefit did not clearly differ across the major immunohistochemistry-defined surrogate subtypes examined.

Researchers analyzed 3,803 patients from the Shanghai Jiao Tong University Breast Cancer Database who received neoadjuvant therapy followed by surgery. Pathological complete response, or pCR, was defined in the study as the absence of invasive disease in both the breast and the lymph nodes, specifically ypT0/is ypN0, meaning no invasive residual tumor in the breast and no involved nodes.

Overall, 908 patients achieved pCR, a rate of 23.88 percent. The frequency of pCR differed significantly across the immunohistochemistry-defined surrogate subtypes of breast cancer, with a P value below 0.001, confirming that how often patients reach a complete pathological response depends strongly on the biological subtype of their tumor.

During a median follow-up of 46 months, achieving pCR was associated with markedly better outcomes. In multivariable Cox regression models, patients with pCR had a 63 percent lower hazard of recurrence, with an adjusted hazard ratio of 0.37 (95 percent confidence interval 0.24 to 0.57) for recurrence-free survival, and a 70 percent lower hazard of dying from breast cancer, with an adjusted hazard ratio of 0.30 (95 percent confidence interval 0.18 to 0.50); both associations were statistically significant at P below 0.001.

The team also ran a series of sensitivity analyses to test the robustness of these findings. Exploratory propensity score matching produced 907 matched pairs, and within these matched pairs the robust hazard ratios were 0.43 (95 percent confidence interval 0.27 to 0.69) for recurrence-free survival and 0.38 (95 percent confidence interval 0.22 to 0.64) for breast cancer-specific survival. Additional analyses using overlap weighting, calendar-year adjustment, and subtype-stratified Cox models yielded consistent associations.

A key question was whether the survival benefit of pCR varies by tumor subtype. To address this, the investigators performed exploratory global subtype-by-pCR interaction tests. These tests were restricted to four subtypes in which within-subtype pCR contrasts could be estimated. The results showed no statistical evidence of heterogeneity in the pCR-survival association across these four subtypes, with a P value for interaction of 0.665 for recurrence-free survival and 0.718 for breast cancer-specific survival.

One subtype could not be included in these interaction analyses. Among the five patients with Luminal A-like disease who achieved pCR, no recurrence-free survival or breast cancer-specific survival events occurred, making the within-subtype contrast impossible to estimate. The authors emphasize that the interaction analyses did not establish effect modification among the four included subtypes and that subtype-specific survival estimates remain exploratory.

As a retrospective, multicenter cohort study, the work has inherent limitations. Even so, the authors note that subtype-specific survival estimates require confirmation in adequately powered studies before firm conclusions can be drawn about differential effects across subtypes.

The study’s central conclusion is twofold: pCR frequency varied substantially across IHC-defined surrogate subtypes, and pCR was associated with favorable recurrence-free and breast cancer-specific survival in the overall cohort. For clinicians and researchers, the findings reinforce the value of pCR as a prognostic marker after neoadjuvant therapy, while cautioning against overinterpreting the exploratory subtype-level analyses until larger, adequately powered studies can verify whether the magnitude of the survival benefit truly differs among breast cancer subtypes.

Subject of Research: Pathological complete response after neoadjuvant therapy for breast cancer and its association with survival outcomes across immunohistochemistry-defined subtypes.

Article Title: Pathological complete response and long-term outcomes after neoadjuvant therapy for breast cancer: a multicenter retrospective cohort study with exploratory subtype analyses

Article References: Fu, S., Xiao, K., Huang, S., Chen, Z., Chen, D., & Lian, W. (2026). Pathological complete response and long-term outcomes after neoadjuvant therapy for breast cancer: a multicenter retrospective cohort study with exploratory subtype analyses. Frontiers in Oncology, 16, Article 1994688. https://doi.org/10.3389/fonc.2026.1994688

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1994688

Keywords: breast cancer, pathological complete response, neoadjuvant therapy, recurrence-free survival, breast cancer-specific survival, tumor subtypes, retrospective cohort study, propensity score matching, immunohistochemistry, prognosis, Pathological, complete